Ra­maswamy notch­es his 5th biotech start­up in 3 years af­ter ink­ing a deal with Mer­ck for PhI­II urol­o­gy drug

Vivek Ra­maswamy has launched an­oth­er new biotech com­pa­ny.

Ra­maswamy’s um­brel­la group Roivant Sci­ences notched its 5th “-vant” start­up — Urovant Sci­ences — af­ter bag­ging a Phase III-ready urol­o­gy drug from Mer­ck.

Talk­ing from the tar­mac as he was prepar­ing to jet his way to Eu­rope, the 30-some­thing en­tre­pre­neur tells me you can now ex­pect the busi­ness de­vel­op­ment team at Basel-based Roivant to go af­ter more deals to beef up the pipeline — a strat­e­gy that has marked his first four com­pa­ny launch­es over just the last three years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.